From: Methylation-associated Has-miR-9 deregulation in paclitaxel- resistant epithelial ovarian carcinoma
PFS | OS | |||
---|---|---|---|---|
HR(95 % CI) | P value | HR(95 % CI) | P value | |
Univariate analysis | ||||
Age | 0.98(0.95-1.01) | 0.148 | 0.99(0.96-1.02) | 0.481 |
miR-9(high vs low) | 0.43(0.24-0.77) | 0.005 | 0.43(0.21-0.86) | 0.018 |
Grade1, 2 vs 3 | 0.34(0.17-0.67) | 0.002 | 0.26(0.11-0.64) | 0.003 |
Stage I-II vs III-IV | 0.21(0.07-0.58) | 0.003 | 0.08(0.01-0.61) | 0.015 |
Optimal vs Suboptimal | 0.33 (0.18-0.59) | 0.000 | 0.25 (0.13-0.51) | 0.000 |
Type I vs Type II | 0.52(0.24-1.13) | 0.099 | 0.07(0.01-0.51) | 0.009 |
Multivariate analysis | ||||
miR-9 | 0.24(0.12-0.50) | 0.000 | 0.37(0.18-0.76) | 0.007 |
Stage I-II vs III-IV | 0.31(0.11-0.89) | 0.029 | 0.15(0.02-1.16) | 0.069 |
Optimal vs Suboptimal | 0.24(0.11-0.53) | 0.000 | 0.41(0.20-0.85) | 0.016 |
Type I vs Type II | 0.87(0.38-2.01) | 0.750 | 0.11(0.01-0.78) | 0.028 |